论文部分内容阅读
首例人类化抗体蛋白:由瑞士罗氏公司(Roche)研制用于预防肾移植排斥反应的人类化抗体蛋白12月10日获FDA批准上市。该药,Zenapax,作用于活化的T淋巴细胞并阻止其与
The first humanized antibody protein: The humanized antibody protein developed by Roche to prevent renal transplant rejection was approved by the FDA on December 10. The drug, Zenapax, acts on activated T lymphocytes and blocks it from it